Tags

Type your tag names separated by a space and hit enter

Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance.
Expert Rev Anti Infect Ther. 2006 Apr; 4(2):199-210.ER

Abstract

Praziquantel became available for the treatment of schistosomiasis and other trematode-inflicted diseases in the 1970s. It was revolutionary because it could be administered orally and had very few unwanted side effects. As a result of marked reductions in the price of praziquantel, the rate at which it is used has accelerated greatly in recent years. For the foreseeable future it will be the mainstay of programs designed to control schistosome-induced morbidity, particularly in sub-Saharan Africa where schistosomiasis is heavily endemic. There is currently no evidence to suggest that any schistosomes have developed resistance to praziquantel as a result of its widespread use. Nevertheless, while resistance may not pose an obvious or immediate threat to the usefulness of praziquantel, complacency and a failure to monitor developments may have serious consequences in the longer term since it will be the only drug that is readily available for large-scale treatment of schistosomiasis.

Authors+Show Affiliations

University of Wales Bangor, School of Biological Sciences, Bangor, Gwynedd LL576 2UW, UK. m.doenhoff@bangor.ac.ukNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16597202

Citation

Doenhoff, Michael J., and Livia Pica-Mattoccia. "Praziquantel for the Treatment of Schistosomiasis: Its Use for Control in Areas With Endemic Disease and Prospects for Drug Resistance." Expert Review of Anti-infective Therapy, vol. 4, no. 2, 2006, pp. 199-210.
Doenhoff MJ, Pica-Mattoccia L. Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. Expert Rev Anti Infect Ther. 2006;4(2):199-210.
Doenhoff, M. J., & Pica-Mattoccia, L. (2006). Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. Expert Review of Anti-infective Therapy, 4(2), 199-210.
Doenhoff MJ, Pica-Mattoccia L. Praziquantel for the Treatment of Schistosomiasis: Its Use for Control in Areas With Endemic Disease and Prospects for Drug Resistance. Expert Rev Anti Infect Ther. 2006;4(2):199-210. PubMed PMID: 16597202.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. AU - Doenhoff,Michael J, AU - Pica-Mattoccia,Livia, PY - 2006/4/7/pubmed PY - 2006/7/27/medline PY - 2006/4/7/entrez SP - 199 EP - 210 JF - Expert review of anti-infective therapy JO - Expert Rev Anti Infect Ther VL - 4 IS - 2 N2 - Praziquantel became available for the treatment of schistosomiasis and other trematode-inflicted diseases in the 1970s. It was revolutionary because it could be administered orally and had very few unwanted side effects. As a result of marked reductions in the price of praziquantel, the rate at which it is used has accelerated greatly in recent years. For the foreseeable future it will be the mainstay of programs designed to control schistosome-induced morbidity, particularly in sub-Saharan Africa where schistosomiasis is heavily endemic. There is currently no evidence to suggest that any schistosomes have developed resistance to praziquantel as a result of its widespread use. Nevertheless, while resistance may not pose an obvious or immediate threat to the usefulness of praziquantel, complacency and a failure to monitor developments may have serious consequences in the longer term since it will be the only drug that is readily available for large-scale treatment of schistosomiasis. SN - 1744-8336 UR - https://www.unboundmedicine.com/medline/citation/16597202/Praziquantel_for_the_treatment_of_schistosomiasis:_its_use_for_control_in_areas_with_endemic_disease_and_prospects_for_drug_resistance_ L2 - https://www.tandfonline.com/doi/full/10.1586/14787210.4.2.199 DB - PRIME DP - Unbound Medicine ER -